The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute
Issue link: https://lifescienceleadermag.epubxp.com/i/792774
CAPABILITIES COMPATIBILITY DEVELOPMENT EXPERTISE RELIABILITY K E Y W W W.C M O L E A D E R S H I PA W A R D S .C O M 2017 CMO LEADERSHIP AWARDS WINNERS 54 LIFESCIENCELEADER.COM THE CMO LEADERSHIP AWARDS 2017 QUALITY Company Profiles DRUG LIFE CYCLE STAGES: Research & Development: Discovery, Pre- Clinical, Clinical (Phase 1, Phase 2, Phase 3) Drug Substance Production: Primary Process Development SERVICES & CAPABILITIES: aseptic fill/finish, injectables, liquids, proteins, vaccines, cell line devel- opment using Freedom® CHO-S®, microbial strain development using GeneGPS Codon Optimization Technology (DNA2.0), & Cytovance® Biologics' Keystone Expression System™, research cell bank production, process development, process optimiza- tion using statistical Design-of-Experiments (DoE), technology transfer, scaled-down model development & process characterization using a QbD framework. "We are ecstatic to be recognized as a CMO Award winner. This honor is a reflection of our dedication to providing quality and reliability and maintain- ing our core competency for all of our clients. These awards would not be possible if it weren't for our highly experienced employees who give effortlessly in meeting our clients' daily needs. We accept these awards on behalf of the dedication and hard work of many within our remarkable company." DRUG TYPE: Biopharmaceuticals DARREN HEAD President & CEO CATEGORIES WON: Cytovance Biologics Inc., a Hepalink Company Oklahoma City, OK www.cytovance.com Phone: +1 405 319 8310 Contact: Valerie McDonnell Email: vmcdonnell@cytovance.com Key locations: Oklahoma City, OK INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, cultural fit DRUG LIFE CYCLE STAGES: Research & Development: Discovery, Pre- Clinical, Clinical (Phase 1, Phase 2, Phase 3) Drug Substance Production: Primary Process Development, Drug Substance Production Formulated Drug Production: Dosage Form Development, Dosage Form Production SERVICES & CAPABILITIES: aseptic fill/fin- ish, capsules, controlled substances, creams & ointments, gels, generics, injectables, liquids, lyophilized products, non-sterile, ophthalmics, OTC, parenterals: large volume, parenterals: small volume, peptides, powders: non-sterile, powders: sterile, proteins, semisolids, soft gels, solid dose, solutions & suspensions, sterile, sustained release, topicals, vaccines "We are very honored to have been recognized for the second consecutive year in five major catego- ries. The 2017 award validates Dalton's manage- ment team's goals to continuing to build a culture of excellence, and demonstrates our ongoing commitment to providing high quality, reliable, cost-effective integrated solutions for our clients' drug development and manufacturing projects." DRUG TYPE: Pharmaceuticals, Biopharmaceuticals PETER PEKOS President & CEO CATEGORIES WON: Dalton Pharma Services Toronto, ON, Canada www.dalton.com Phone: +1 416 661 2102 Contact: Kavvita Santilli Email: ksantilli@dalton.com Key locations: Toronto, ON, Canada INDIVIDUAL ATTRIBUTE AWARDS: innovation, on-time, reputation, strength of science DRUG LIFE CYCLE STAGES: Research & Development: Clinical (Phase 2, Phase 3) Drug Substance Production: Primary Process Development, Drug Substance Production Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging SERVICES & CAPABILITIES: aseptic fill/finish, capsules, controlled substances, creams & oint- ments, cytotoxic & high potency compounds, gels, generics, injectables, liquids, lyophilized products, non-sterile, ophthalmics, OTC, parenterals: large volume, parenterals: small volume, powders: non- sterile, powders: sterile, semisolids, solid dose, solutions & suspensions, sterile, sustained release, syringes: prefilled, topicals "Fareva's success in contract manufacturing for our API and Pharma customers is based on the experience and the creativity of our teams in development, manufacturing, and regulatory affairs and they allow us to consistently provide innovative solutions. Besides flawless and reliable supply, Fareva has established a position as a long-term preferred supplier by building relation- ships based on clear and open communications, vital to continuously meeting the wide-ranging needs of our customers." DRUG TYPE: Pharmaceuticals BERNARD FRAISSE President & CEO CATEGORIES WON: Fareva Tournon sur Rhône, France www.fareva.com Phone: +1 919 768 6858 Contact: George Hlass Email: ghlass.usa@fareva.com Key locations: France, Germany, Italy, United States INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, cultural fit, innovation, on-time, reputation, right first time